Biopharmaceuticals Stocks List

Recent Signals

Date Stock Signal Type
2021-05-14 ABEO Stochastic Buy Signal Bullish
2021-05-14 AMTI 20 DMA Resistance Bearish
2021-05-14 BMRN Lower Bollinger Band Walk Weakness
2021-05-14 BMRN Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 DYAI New 52 Week Closing Low Bearish
2021-05-14 DYAI New 52 Week Low Weakness
2021-05-14 DYAI Lower Bollinger Band Walk Weakness
2021-05-14 EIGR NR7-2 Range Contraction
2021-05-14 EIGR Narrow Range Bar Range Contraction
2021-05-14 EIGR NR7 Range Contraction
2021-05-14 IBIO Calm After Storm Range Contraction
2021-05-14 IBIO 50 DMA Resistance Bearish
2021-05-14 LVTX 20 DMA Support Bullish
2021-05-14 NAVB Lower Bollinger Band Walk Weakness
2021-05-14 NAVB Bollinger Band Squeeze Range Contraction
2021-05-14 NGM Spinning Top Other
2021-05-14 NGM Bollinger Band Squeeze Range Contraction
2021-05-14 NGM MACD Bullish Centerline Cross Bullish
2021-05-14 NGM 50 DMA Support Bullish
2021-05-14 NVO New 52 Week High Strength
2021-05-14 NVO New 52 Week Closing High Bullish
2021-05-14 NVO Upper Bollinger Band Walk Strength
2021-05-14 NVO Lizard Bearish Bearish Day Trade Setup
2021-05-14 NVO Shooting Star Candlestick Bearish
2021-05-14 NVO Narrow Range Bar Range Contraction
2021-05-14 NVO NR7 Range Contraction
2021-05-14 XTLB 50 DMA Resistance Bearish
2021-05-14 XTLB 20 DMA Resistance Bearish

Recent News for Biopharmaceuticals Stocks

Date Stock Title
May 17 IBIO iBio, Inc. (IBIO) CEO Thomas Isett on Q3 2021 Results - Earnings Call Transcript
May 17 IBIO iBio Q1 net loss widens as expenses soar year-over-year; shares fall 6%
May 17 IBIO iBio revenue in-line
May 17 IBIO iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update
May 14 NGM Does NGM Biopharmaceuticals' (NASDAQ:NGM) Share Price Gain of 28% Match Its Business Performance?
May 14 DYAI Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2021 Results - Earnings Call Transcript
May 13 AMTI Applied Molecular Transport EPS beats by $0.17
May 13 NVO Novo Nordisk, Eli Lilly Obesity Drugs Could Be Game Changers
May 13 DYAI Dyadic International reports Q1 results
May 13 AMTI Applied Molecular Transport Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13 DYAI Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
May 13 DYAI Dyadic International, Inc. to Host Earnings Call
May 13 NVO Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis
May 12 BMRN BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting
May 12 NAVB Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2021 Results - Earnings Call Transcript
May 11 NAVB Navidea Q1 loss widens as revenue drops, R&D expenses rise
May 11 NAVB Navidea Biopharm EPS misses by $0.03, misses on revenue
May 11 NAVB Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
May 11 NAVB Navidea Biopharmaceuticals, Inc. to Host Earnings Call
May 11 NAVB Navidea Bio reports NIH grant to evaluate Tc99m tilmanocept as a kidney imaging agent
Related Industries: Biotechnology Metal Fabrication

A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.
Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Specialty drugs, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics. The European Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are "based on genes, cells, or tissue engineering", including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. Within EMA contexts, the term advanced therapies refers specifically to ATMPs, although that term is rather nonspecific outside those contexts.
Gene-based and cellular biologics, for example, often are at the forefront of biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available.In some jurisdictions, biologics are regulated via different pathways than other small molecule drugs and medical devices.The term biopharmacology is sometimes used to describe the branch of pharmacology that studies biopharmaceuticals.

More about Biopharmaceuticals
Browse All Tags